Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPORT: Postoperative Radiotherapy with Concurrent JS001 in HNSCC
NCT04523883Phase 2Unknown
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Aug 2020
- Primary completion
- Aug 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in head and neck squamous cell carcinoma (HNSCC), sponsored by Shanghai Ninth People's Hospital. Status: unknown.
02
Drugs
toripalimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04523883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04523883.